BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19254225)

  • 1. [Is the combination of benazepril and amlodipine more effective in hypertension than the combination of benazepril and hydrochlorothiazide? Results of the ACCOMPLISH trial].
    Preobrazhenskiĭ DV
    Kardiologiia; 2009; 49(2):81-2. PubMed ID: 19254225
    [No Abstract]   [Full Text] [Related]  

  • 2. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
    Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
    N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
    Strauss MH; Weinstein J; Newton GE
    N Engl J Med; 2009 Mar; 360(11):1148; author reply 1149-50. PubMed ID: 19283888
    [No Abstract]   [Full Text] [Related]  

  • 4. Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
    Parra D; Rosenstein R
    N Engl J Med; 2009 Mar; 360(11):1147-8; author reply 1149-50. PubMed ID: 19279348
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination therapy with amlodipine/benazapril (CCB/ACEI) superior to hydrochlorothiazide/benazapril in high-risk hypertensive patients.
    Cardiovasc J Afr; 2008; 19(3):163. PubMed ID: 18568181
    [No Abstract]   [Full Text] [Related]  

  • 6. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
    Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
    J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
    Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
    J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The ACCOMPLISH trial: are results really unexpected?].
    Waeber B; Feihl F
    Rev Med Suisse; 2009 Jan; 5(185):25-8. PubMed ID: 19216321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does it matter how hypertension is controlled?
    Chobanian AV
    N Engl J Med; 2008 Dec; 359(23):2485-8. PubMed ID: 19052130
    [No Abstract]   [Full Text] [Related]  

  • 10. Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
    Davis BR; Whelton PK;
    N Engl J Med; 2009 Mar; 360(11):1148-9; author reply 1149-50. PubMed ID: 19283889
    [No Abstract]   [Full Text] [Related]  

  • 11. Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension.
    Reichek N; Devereux RB; Rocha RA; Hilkert R; Hall D; Purkayastha D; Pitt B
    Hypertension; 2009 Oct; 54(4):731-7. PubMed ID: 19687350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACCOMPLISH the goal: hypertension and beyond.
    Siragy HM
    Curr Hypertens Rep; 2009 Aug; 11(4):231-2. PubMed ID: 19602321
    [No Abstract]   [Full Text] [Related]  

  • 13. Will the results of the ACCOMPLISH trial affect the recommendations of JNC 8?
    Cohen DL; Townsend RR
    J Clin Hypertens (Greenwich); 2009 Feb; 11(2):100-1. PubMed ID: 19222676
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
    Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
    Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal outcomes in hypertensive Black patients at high cardiovascular risk.
    Weir MR; Bakris GL; Weber MA; Dahlof B; Devereux RB; Kjeldsen SE; Pitt B; Wright JT; Kelly RY; Hua TA; Hester RA; Velazquez E; Jamerson KA
    Kidney Int; 2012 Mar; 81(6):568-76. PubMed ID: 22189843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension.
    Byrd JB; Bakris G; Jamerson K
    Curr Hypertens Rep; 2014 Mar; 16(3):419. PubMed ID: 24474031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.
    Messerli FH; Oparil S; Feng Z
    Am J Cardiol; 2000 Dec; 86(11):1182-7. PubMed ID: 11090788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
    Bakris GL; Toto RD; McCullough PA; Rocha R; Purkayastha D; Davis P;
    Kidney Int; 2008 Jun; 73(11):1303-9. PubMed ID: 18354383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
    Chrysant SG; Bakris GL
    Am J Hypertens; 2004 Jul; 17(7):590-6. PubMed ID: 15233978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control.
    Jamerson KA; Devereux R; Bakris GL; Dahlöf B; Pitt B; Velazquez EJ; Weir M; Kelly RY; Hua TA; Hester A; Weber MA
    Hypertension; 2011 Feb; 57(2):174-9. PubMed ID: 21189401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.